Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Dow
AstraZeneca
Chinese Patent Office
Teva
Novartis
Cipla
Fish and Richardson
Baxter
Covington

Generated: August 17, 2017

DrugPatentWatch Database Preview

PROTOPAM CHLORIDE Drug Profile

« Back to Dashboard

What is the patent landscape for Protopam Chloride, and what generic Protopam Chloride alternatives are available?

Protopam Chloride is a drug marketed by Wyeth Ayerst and Baxter Hlthcare Corp and is included in two NDAs.

The generic ingredient in PROTOPAM CHLORIDE is pralidoxime chloride. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pralidoxime chloride profile page.

Summary for Tradename: PROTOPAM CHLORIDE

Patents:0
Applicants:2
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list33
Clinical Trials: see list454
Patent Applications: see list351
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PROTOPAM CHLORIDE at DailyMed

Pharmacology for Tradename: PROTOPAM CHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Ayerst
PROTOPAM CHLORIDE
pralidoxime chloride
TABLET;ORAL014122-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare Corp
PROTOPAM CHLORIDE
pralidoxime chloride
INJECTABLE;INJECTION014134-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Cipla
Fish and Richardson
Daiichi Sankyo
AstraZeneca
Dow
Accenture
Citi
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot